Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. Welcome. I'm Jess Fye, senior biotech analyst at JPMorgan. And we're continuing the conference this morning with Intra-Cellular. I'm joined by the company's CEO, Sharon Mates. She's going to give a presentation on the business, and then we're going to go into Q&A.
(Conference Instructions) So with that, let me pass it over to Sharon.
Thanks, Jessica. It's great to be here today. And I am joined by my colleagues, Mark Neumann, our Chief Commercial Officer; and Suresh Durgam, our Chief Medical Officer.
So before I begin, I should tell you that our presentation today does contain forward-looking statements and actual results may differ. And I refer you to our website and to our SEC filings for continuous updates on the company.
So today, I'm going to tell you about Intra-Cellular Therapies and about the great progress we've made and what we think is a great year that we've had
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |